On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...